Jacob Centra

Jacob Centra

Auto-generated profile, based on publicly available information

Jacob Centra

Digital Medicine Society, Boston, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
JBJessie P. Bakker
Jessie P. Bakker
RBRoland Barge
Roland Barge
JCJacob Centra
Jacob Centra
BCBryan Cobb
Bryan Cobb
CCChas Cota
Chas Cota
JGJennifer C. Goldsack
Jennifer C. Goldsack
We propose the addition of usability validation to the extended V3 framework, now “V3+”, and describe a pragmatic approach to ensuring that sensor-based digital health technologies can be used optimally at scale by diverse users. Alongside the original V3 components (verification; analytical validation; clinical validation), usability validation will ensure user-centricity of digital measurement tools, paving the way for more inclusive, reliable, and trustworthy digital measures within clinical research and clinical care.

15 November 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ATAnimesh Tandon
Animesh Tandon
BCBryan Cobb
Bryan Cobb
JCJacob Centra
Jacob Centra
EIElena Izmailova
Elena Izmailova
NMNikolay Manyakov
Nikolay Manyakov
DDDigital Health Measurement Collaborative Community (DATAcc) hosted by DiMe
Digital Health Measurement Collaborative Community (DATAcc) hosted by DiMe
Background: Increasing adoption of sensor-based digital health technologies (sDHTs) in recent years has cast light on the many challenges in implementing these tools into clinical trials and patient care at scale across diverse patient populations; however, the methodological approaches taken toward sDHT usability evaluation have varied markedly. Objective: This review aims to explore the current landscape of studies reporting data related to sDHT human factors, human-centered design, and usability, to inform our concurrent work on developing an evaluation framework for sDHT usability. Methods: We conducted a scoping review of studies published between 2013 and 2023 and indexed in PubMed, in which data related to sDHT human factors, human-centered design, and usability were reported. Following a systematic screening process, we extracted the study design, participant sample, the sDHT or sDHTs used, the methods of data capture, and the types of usability-related data captured. Results: Our literature search returned 442 papers, of which 85 papers were found to be eligible and 83 papers were available for data extraction and not under embargo. In total, 164 sDHTs were evaluated; 141 (86%) sDHTs were wearable tools while the remaining 23 (14%) sDHTs were ambient tools. The majority of studies (55/83, 66%) reported summative evaluations of final-design sDHTs. Almost all studies (82/83, 99%) captured data from targeted end users, but only 18 (22%) out of 83 studies captured data from additional users such as care partners or clinicians. User satisfaction and ease of use were evaluated for 83% (136/164) and 91% (150/164) of sDHTs, respectively; however, learnability, efficiency, and memorability were reported for only 11 (7%), 4 (2%), and 2 (1%) out of 164 sDHTs, respectively. A total of 14 (9%) out of 164 sDHTs were evaluated according to the extent to which users were able to understand the clinical data or other information presented to them (understandability) or the actions or tasks they should complete in response (actionability). Notable gaps in reporting included the absence of a sample size rationale (reported for 21/83, 25% of all studies and 17/55, 31% of summative studies) and incomplete sociodemographic descriptive data (complete age, sex/gender, and race/ethnicity reported for 14/83, 17% of studies). Conclusions: Based on our findings, we suggest four actionable recommendations for future studies that will help to advance the implementation of sDHTs: (1) consider an in-depth assessment of technology usability beyond user satisfaction and ease of use, (2) expand recruitment to include important user groups such as clinicians and care partners, (3) report the rationale for key study design considerations including the sample size, and (4) provide rich descriptive statistics regarding the study sample to allow a complete understanding of generalizability to other patient populations and contexts of use.

22 February 2024 in JMIR Preprints
Verified
Preprint
Open access
ATAnimesh Tandon
Animesh Tandon
BCBryan Cobb
Bryan Cobb
JCJacob Centra
Jacob Centra
EIElena Izmailova
Elena Izmailova
NMNikolay Manyakov
Nikolay Manyakov
JBJessie P Bakker
Jessie P Bakker
BACKGROUND Increasing adoption of sensor-based digital health technologies (sDHTs) in recent years has cast light on the many challenges in implementing these tools into clinical trials and patient care at scale across diverse patient populations; however, the methodological approaches taken toward sDHT usability evaluation have varied markedly. OBJECTIVE This review aims to explore the current landscape of studies reporting data related to sDHT human factors, human-centered design, and usability, to inform our concurrent work on developing an evaluation framework for sDHT usability. METHODS We conducted a scoping review of studies published between 2013 and 2023 and indexed in PubMed, in which data related to sDHT human factors, human-centered design, and usability were reported. Following a systematic screening process, we extracted the study design, participant sample, the sDHT or sDHTs used, the methods of data capture, and the types of usability-related data captured. RESULTS Our literature search returned 442 papers, of which 85 papers were found to be eligible and 83 papers were available for data extraction and not under embargo. In total, 164 sDHTs were evaluated; 141 (86%) sDHTs were wearable tools while the remaining 23 (14%) sDHTs were ambient tools. The majority of studies (55/83, 66%) reported summative evaluations of final-design sDHTs. Almost all studies (82/83, 99%) captured data from targeted end users, but only 18 (22%) out of 83 studies captured data from additional users such as care partners or clinicians. User satisfaction and ease of use were evaluated for 83% (136/164) and 91% (150/164) of sDHTs, respectively; however, learnability, efficiency, and memorability were reported for only 11 (7%), 4 (2%), and 2 (1%) out of 164 sDHTs, respectively. A total of 14 (9%) out of 164 sDHTs were evaluated according to the extent to which users were able to understand the clinical data or other information presented to them (understandability) or the actions or tasks they should complete in response (actionability). Notable gaps in reporting included the absence of a sample size rationale (reported for 21/83, 25% of all studies and 17/55, 31% of summative studies) and incomplete sociodemographic descriptive data (complete age, sex/gender, and race/ethnicity reported for 14/83, 17% of studies). CONCLUSIONS Based on our findings, we suggest four actionable recommendations for future studies that will help to advance the implementation of sDHTs: (1) consider an in-depth assessment of technology usability beyond user satisfaction and ease of use, (2) expand recruitment to include important user groups such as clinicians and care partners, (3) report the rationale for key study design considerations including the sample size, and (4) provide rich descriptive statistics regarding the study sample to allow a complete understanding of generalizability to other patient populations and contexts of use.

24 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ATAnimesh Tandon
Animesh Tandon
BCBryan R Cobb
Bryan R Cobb
JCJacob Centra
Jacob Centra
EIElena Izmailova
Elena Izmailova
NMNikolay Manyakov
Nikolay Manyakov
T(the Digital Health Measurement Collaborative Community hosted by the Digital Medicine Society (DiMe)
the Digital Health Measurement Collaborative Community hosted by the Digital Medicine Society (DiMe)
Background Increasing adoption of sensor-based digital health technologies (sDHTs) in recent years has cast light on the many challenges in implementing these tools into clinical trials and patient care at scale across diverse patient populations; however, the methodological approaches taken towards sDHT usability evaluation have varied markedly. Objective To elucidate the current landscape of studies reporting data related to sDHT human factors, human-centered design, and/or usability. Methods We conducted a systematic scoping review of studies published between 2013 and 2023 and indexed in PubMed, in which data related to sDHT human factors, human-centered design, and/or usability were reported. Following a systematic screening process, we extracted the study design; participant sample; the sDHT(s) used; the method(s) of data capture; and the type(s) of usability-related data captured. Results Our literature search returned 442 papers, of which 85 were found to be eligible and 83 were available for data extraction and not under embargo. In total, 164 sDHTs were evaluated; 141 were wearable tools while the remaining 23 were ambient tools. The majority of studies (n=55; 66%) reported summative evaluations of final-design sDHTs. Almost all studies (n=82; 98%) captured data from targeted end-users, but only 18 (22%) captured data from additional users such as carepartners or clinicians. User satisfaction and ease of use were evaluated for >80% of sDHTs; however, learnability, eficiency, and memorability were reported for only 11 (13%), 4 (5%), and 2 sDHTs (2%), respectively. Fourteen sDHTs (17%) were evaluated according to the extent to which users were able to understand the clinical data or other information presented to them (understandability) and/or the actions or tasks they should complete in response (actionability). Notable gaps in reporting included the absence of a sample size rationale (reported for 25% of all studies and 31% of summative studies) and incomplete sociodemographic descriptive data (complete age, sex/gender, and race/ethnicity reported for 17% of studies). Conclusions Based on our findings, we suggest four actionable recommendations for future studies that will help to advance the implementation of sDHTs: 1) Consider in-depth assessment of technology usability beyond user satisfaction and ease of use; 2) Expand recruitment to include important user groups such as clinicians and carepartners; 3) Report the rationale for key study design considerations including the sample size; and 4) Provide rich descriptive statistics regarding the study sample to allow a complete understanding of generalizability to other patient populations and contexts of use.

29 March 2024 in JMIR Preprints
Verified
Preprint
Open access
SSSarah M Sheehan
Sarah M Sheehan
JCJacob Centra
Jacob Centra
KDKarrie Dudek
Karrie Dudek
KAKimlin Ashing
Kimlin Ashing
SBShaalan Beg
Shaalan Beg
CLCorinne R Leach
Corinne R Leach
BACKGROUND The use of digital health solutions by providers, health system staff, patients, and caregivers promises more equitable access to comprehensive cancer care and a positive impact on out-of-pocket costs for patients.The use of digital solutions within healthcare systems to improve equitable access to care and prevent or reduce costs that cause financial toxicity also has positive implications for health system cost savings, driven mostly by increased efficiency and revenue generation. OBJECTIVE To examine and document the impact of digital health solutions on access to cancer care, access to cancer clinical trials, and cancer-related financial toxicity, as well as any barriers and facilitators to digital health solution uptake. METHODS We searched PubMed for peer-reviewed articles published between 2018 and 2023 that described the effect of digital health solutions on access to cancer care, access to cancer clinical trials, and cancer-related financial toxicity. We included US-based studies written in English and pertaining to adult cancer patients. Articles were analyzed to document the effect of digital health solutions being used in oncology to impact access to cancer care, access to cancer clinical trials, and cancer-related financial toxicity, as well as any barriers to solution uptake. We reported findings in accordance with the PRISMA- ScR checklist. RESULTS Our search identified a total of 1009 unique records and we selected 136 after a title and abstract screen and full-text review. The vast majority of articles that studied the relationship between digital solutions and access to care (approximately 88%; 116/132) found that access to high-quality cancer care is potentiated by the purposeful implementation of digital health solutions. 93% (39/42) of articles examining the relationship between digital solutions and the cost dimension of patient financial toxicity found a positive impact. In this review, we discuss end-user characteristics, solution types, and the dimensions of digital health solution impact on patient access and cost, such as expedited access to cancer care and cost savings associated with averted travel and fewer work disruptions. CONCLUSIONS When cancer care is appropriately available to patients through digital interactions and integrated into patient and family life, access to high-quality care can be enhanced at a lower overall cost. To ensure that the positive effects of digital transformation in cancer care extend to all patient subsets, it is essential to address the factors that drive inequitable patient access to both digital health solutions and care. Going forward, a focus on health ecosystem policies to overcome identified barriers to uptake, including technology and internet access, and effective education to ensure technical proficiency, is essential.